Not an SEC registrant

PANTHERx Specialty Pharmacy LLC

Customers

None disclosed

Suppliers

1 disclosed

Latest period

Mar 31, 2026

10-Q filed 2026-05-07

Band height is the estimated dollar value: the disclosed share × the discloser's revenue for that period (latest full year where available) or federal dollars obligated. Each side is scaled on its own; dashed outlines are named without a figure. Click a band to open its source.

Suppliers 1

Companies that disclose PANTHERx Specialty Pharmacy LLC as a major customer, as a share of their own revenue. 1 active, 0 lapsed.

Company	% of their revenue	Est. $ from PANTHERx Specialty Pharmacy LLC	Period	Trend	Status	Source
HRMY Harmony Biosciences Holdings, Inc.	Named	—	3M 2026-03-31	−1.0pp	Active	10-Q 2026-05-07
Caremark LLC (“CVS Caremark”), which accounted for 33% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 26% of gross accounts receivable. 10-Q filed 2026-05-07 Period 3M 2026-01-01 to 2026-03-31Accession 0001104659-26-056720 Accredo Health Group, Inc. accounted for 36% of gross product revenue; and PANTHERx Specialty Pharmacy LLC accounted for 26% of gross product revenue. 10-K filed 2026-02-24 Period FY 2025-01-01 to 2025-12-31 (26%)Accession 0001104659-26-018859 Accredo Health Group, Inc. (“Accredo”), which accounted for 32% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 28% of gross accounts receivable. 10-Q filed 2025-05-06 Period 3M 2025-01-01 to 2025-03-31Accession 0001558370-25-006394 Accredo Health Group, Inc. accounted for 34% of gross product revenue; and PANTHERx Specialty Pharmacy LLC accounted for 27% of gross product revenue. 10-K filed 2025-02-25 Period FY 2024-01-01 to 2024-12-31 (27%)Accession 0001558370-25-001441 Accredo Health Group, Inc. (“Accredo”), which accounted for 36% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 23% of gross accounts receivable. 10-Q filed 2024-04-30 Period 3M 2024-01-01 to 2024-03-31Accession 0001558370-24-006203 PANTHERx Specialty Pharmacy LLC (“PANTHERx”), which accounted for 31% of gross accounts receivable; and Accredo Health Group, Inc. (“Accredo), which accounted for 30% of gross accounts receivable. 10-K filed 2025-02-25 Period FY 2023-01-01 to 2023-12-31 (31%)Accession 0001558370-25-001441 Caremark LLC (“CVS Caremark”), which accounted for 30% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 29% of gross accounts receivable. 10-Q filed 2023-05-02 Period 3M 2023-01-01 to 2023-03-31Accession 0001558370-23-007571 Caremark LLC (“CVS Caremark”), which accounted for 32% of gross accounts receivable; and PANTHERX Specialty Pharmacy LLC (“Pantherx), which accounted for 29% of gross accounts receivable. 10-K filed 2024-02-22 Period FY 2022-01-01 to 2022-12-31 (29%)Accession 0001558370-24-001466 Accredo Health Group, Inc. (“Accredo”), which accounted for 32% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 30% of gross accounts receivable. 10-Q filed 2022-05-03 Period 3M 2022-01-01 to 2022-03-31 (32%)Accession 0001558370-22-006729 Accredo Health Group, Inc. (“Accredo”), which accounted for 35% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 24% of gross accounts receivable. 10-K filed 2023-02-21 Period FY 2021-01-01 to 2021-12-31 (35%)Accession 0001558370-23-001574

Alerts are coming

Get an email when PANTHERx Specialty Pharmacy LLC's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.